ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

7 links0 made here, not in the record10 judgments2 judges (our rules as one)1 record change seen
Claude Opus 5.5Our rulesRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT04042116A Study to EvaluateLucitanib in CombinationWith Nivolumab in PatientsWith a Solid TumorClovis Oncology, Inc.Phase 1/Phase 2 · suspendedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedMeSH filing re-derivedCONDITIONSGenital Neoplasms, FemaleThe registry's MeSH filing›Nov 14 · Our condition-kind rule · Wider: a narrower term is filedAs of now · Our main-condition rule (R9) · Main conditionMain conditionOvarian NeoplasmsThe registry's MeSH filing›Nov 14 · Our condition-kind rule · Finest filed termFinest filed termFallopian Tube NeoplasmsThe registry's MeSH filing›Nov 14 · Our condition-kind rule · Finest filed termFinest filed termEndometrial NeoplasmsThe registry's MeSH filing›Nov 14 · Our condition-kind rule · Finest filed termFinest filed termUterine Cervical NeoplasmsThe registry's MeSH filing›Nov 14 · Our condition-kind rule · Finest filed termFinest filed termDRUGSE-3810Entry “Lucitanib”, read by our name r…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Our role rule · TestedTestedNivolumabIntervention entry›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Our role rule · TestedBackground · partner

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

E-3810

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Lucitanib”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2E-3810Claude Opus 5.5TestedCurrent
Nov 2NivolumabClaude Opus 5.5Background · partnerCurrent
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 14Genital Neoplasms, FemaleOur condition-kind ruleWider: a narrower term is filedCurrent
Nov 14Ovarian NeoplasmsOur condition-kind ruleFinest filed termCurrent
Nov 14Fallopian Tube NeoplasmsOur condition-kind ruleFinest filed termCurrent
Nov 14Endometrial NeoplasmsOur condition-kind ruleFinest filed termCurrent
Nov 14Uterine Cervical NeoplasmsOur condition-kind ruleFinest filed termCurrent
Nov 18E-3810Our role ruleTestedAgrees
Nov 18NivolumabOur role ruleTestedOverridden
As of nowGenital Neoplasms, FemaleOur main-condition rule (R9)Main conditionCurrent